Advertisement

FDA Approves Drug to Treat Advanced Stomach Cancer — Physician’s First Watch

Medical News |
April 23, 2014

FDA Approves Drug to Treat Advanced Stomach Cancer

By Kristin J. Kelley

The FDA has approved ramucirumab (Cyramza) to treat unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The drug, which works by blocking the blood supply to tumors, is indicated for patients who have been unsuccessfully treated with fluoropyrimidine- or platinum-containing therapy.

In a placebo-controlled trial, ramucirumab slowed tumor growth and improved survival (median overall survival: 5.2 vs. 3.8 months with placebo). Additionally, in a separate trial, patients treated with ramucirumab plus the chemotherapy drug paclitaxel had better overall survival, compared with those who only received paclitaxel.

The two most common side effects were diarrhea and high blood pressure.

Reader Comments (1)

Dr Rajeev Jain Other Healthcare Professional, Dentistry, jabalapur mp india

Good article

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement